Speculative M&A Transaction Analysis, page-780

Understand your sentiment, but - my opinion only as well - strongly disagree. if you'd said US$10b offer I think it is still be a steal, if data backs up and proves in humans what animal studies showed. While things can go wrong, at the same time things could also open up - like many cancers to be treated as Mason said. While I understand and strongly support that we do not want to wait another 5 to 6 years for a return 2 to 3 years and confirmed Phase 2 data should put us into an excellent position that several BP would see a great opportunity not only to revitalise (and recapitalise) their own and several cases expired or expiring treatments, but get a new one with a very long exclusivity. Now thats worth money, quite a bit, at least as I see and happy to wait for it. By the way, US$10B is the lower end I would entertain if we have the results.